Generic KANAMYCIN SULFATE INN entry, drug patent expiry and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apothecon	KANTREX	kanamycin sulfate	INJECTABLE;INJECTION	062564-003	Sep 21, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Solopak	KANAMYCIN SULFATE	kanamycin sulfate	INJECTABLE;INJECTION	062605-002	Feb 26, 1986		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Abraxis Pharm	KANAMYCIN SULFATE	kanamycin sulfate	INJECTABLE;INJECTION	062504-003	Apr 5, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pharmafair	KANAMYCIN SULFATE	kanamycin sulfate	INJECTABLE;INJECTION	062669-001	May 7, 1987		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Apothecon	KANTREX	kanamycin sulfate	INJECTABLE;INJECTION	062564-001	Sep 21, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Solopak	KANAMYCIN SULFATE	kanamycin sulfate	INJECTABLE;INJECTION	062605-001	Feb 26, 1986		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: October 16, 2026

Kanamycin sulfate is a mature aminoglycoside with minimal branded-pharmaceutical value, no meaningful patent exclusivity, and declining systemic clinical demand. Its remaining commercial activity is concentrated in low-cost generic injectable products, veterinary medicines, laboratory reagents, and limited ophthalmic or topical applications. Public company filings do not provide a reliable product-level revenue series for kanamycin sulfate, so market growth cannot be quantified from audited financial disclosures.

What is the current market position of kanamycin sulfate?

Kanamycin sulfate is an aminoglycoside antibiotic derived from Streptomyces kanamyceticus. It inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. The drug has activity against selected Gram-negative and Gram-positive organisms, but its use is constrained by nephrotoxicity, ototoxicity, injection requirements, and antimicrobial resistance.

Its commercial position differs by application:

Segment	Current market position	Financial outlook
Human injectable antibiotic	Mature, low-volume generic market	Flat to declining
Multidrug-resistant tuberculosis	Largely displaced by newer agents	Structurally declining
Veterinary medicine	Continuing niche demand	Stable in selected regions
Ophthalmic and topical products	Limited and jurisdiction-dependent	Small, fragmented
Research and biotechnology reagent	Recurring laboratory demand	More resilient than clinical demand
Active pharmaceutical ingredient	Commodity supply base	Price-sensitive, low-margin

Kanamycin sulfate is no longer a major growth product in human anti-infectives. The strongest remaining demand comes from markets where low acquisition cost, established manufacturing, and local treatment protocols outweigh toxicity and resistance concerns.

When does kanamycin sulfate lose exclusivity?

Kanamycin sulfate lost meaningful composition-of-matter and product exclusivity decades ago. The active ingredient was introduced in the 1950s, and any original patent protection has long expired.

There is no commercially relevant patent barrier preventing generic manufacture of kanamycin sulfate as an active ingredient. Potential intellectual-property protection is limited to later-developed areas such as:

Specific formulations
Manufacturing or purification processes
Combination products
Delivery devices
Narrow method-of-use claims
Veterinary formulations
Laboratory compositions

These rights generally do not recreate market exclusivity for the underlying antibiotic. A process patent may affect a particular supplier, but it does not prevent alternative production routes where the claims do not cover the competing process.

What patents protect kanamycin sulfate products?

No broad, active patent estate is generally associated with the kanamycin sulfate molecule itself. The relevant commercial issue is regulatory approval and manufacturing economics, not molecule-level patent exclusivity.

Patent categories with possible relevance

Patent category	Relevance to kanamycin sulfate	Commercial impact
Original compound patents	Expired	None
Salt or crystal-form patents	Generally not material for this old product	Low
Injectable formulation patents	Possible but narrow	Product-specific
Ophthalmic delivery patents	Possible	Limited to formulation or device
Manufacturing-process patents	Possible	Supplier-specific
Combination therapy patents	Possible	Dependent on indication
Veterinary-use patents	Possible	Narrow geographic scope

A prospective entrant would typically face regulatory, quality, and supply-chain requirements rather than a blocking patent portfolio. Freedom-to-operate analysis still requires review of jurisdiction-specific patent records, particularly for combination products and specialized delivery systems.

What is the FDA regulatory status of kanamycin sulfate?

The U.S. regulatory position is commercially unfavorable compared with newer antibiotics. Kanamycin sulfate has historically been marketed as an injectable aminoglycoside, but product availability and labeling status have changed over time. FDA databases should be checked for the specific product, manufacturer, National Drug Code, and application status because an ingredient’s historical approval does not establish that a currently marketed product remains available.

Kanamycin products may appear in regulatory records as:

Approved prescription injections
Discontinued or withdrawn products
Unapproved products marketed under legacy or foreign regulatory frameworks
Veterinary drugs regulated separately from human products
Research reagents that are not approved for human use

FDA approval, marketing status, and current commercial availability are separate questions. A product can have an established FDA regulatory history while having limited or no active U.S. commercial distribution.

What is the Orange Book status of kanamycin sulfate?

Kanamycin sulfate does not have a significant Orange Book exclusivity profile comparable with newer branded antibiotics. The key commercial questions are whether an active reference-listed drug exists, whether current abbreviated new drug applications are approved, and whether any listed products remain marketed.

For a generic entrant, the practical analysis should focus on:

Whether an active reference product exists.
Whether an ANDA pathway is available.
Whether the proposed dosage form matches an approved reference.
Whether the product has injectable-drug manufacturing capability.
Whether the applicant can satisfy current sterility and quality requirements.

Because kanamycin sulfate is an old molecule, Paragraph IV litigation is unlikely to be a central market event. Any Paragraph IV filing would more likely concern a later formulation, method of use, or device patent rather than the antibiotic compound.

How many patents cover kanamycin sulfate?

There is no commercially meaningful count of active, blocking patents covering the basic kanamycin sulfate molecule. Historical patent documents may cover the original discovery, fermentation, purification, or early therapeutic uses, but those rights are expired.

Patent counts can be misleading for this product because databases may include:

Expired patents
Foreign counterparts
Abandoned applications
Formulation claims with narrow scope
Patents covering kanamycin among many listed compounds
Research-use compositions
Veterinary or agricultural applications

The relevant question is not the number of documents mentioning kanamycin. It is whether an unexpired claim covers the proposed product, indication, manufacturing route, or delivery system in the target market.

What happened to kanamycin in multidrug-resistant tuberculosis?

Kanamycin was historically used as an injectable second-line treatment for tuberculosis, including multidrug-resistant tuberculosis. Its role declined because of poor tolerability, permanent hearing damage, renal toxicity, injection-related burdens, and resistance.

The World Health Organization moved away from kanamycin and other injectable agents in drug-resistant tuberculosis treatment recommendations. The 2019 WHO consolidated guidelines placed greater emphasis on all-oral regimens and newer medicines such as bedaquiline, linezolid, clofazimine, and delamanid (World Health Organization, 2019).

This change materially reduced the strategic value of kanamycin in tuberculosis markets. Public-health procurement programs that once supported demand for injectable kanamycin increasingly shifted toward oral regimens. That transition removed one of the largest identifiable clinical demand pools.

What formulations are protected by kanamycin sulfate patents?

Commercially relevant formulations may include:

Sterile injectable solutions
Ophthalmic solutions or ointments
Topical preparations
Veterinary injectables
Laboratory selection media
Combination antibiotic products

Formulation-related protection is generally narrow. A claim may cover a particular concentration, excipient system, container, dosing schedule, or delivery mechanism. Such protection does not necessarily prevent sale of a conventional sterile kanamycin sulfate injection.

The most significant barriers for injectable products are often technical rather than patent-based. Manufacturers must demonstrate control of sterility, endotoxins, particulate matter, potency, impurities, container closure, and stability. These requirements can limit the number of qualified suppliers even where the molecule is off patent.

Which companies manufacture or sell kanamycin sulfate?

The market is fragmented among regional generic manufacturers, contract manufacturers, veterinary-drug companies, and chemical suppliers. Major multinational pharmaceutical companies have limited strategic exposure to kanamycin sulfate as a standalone product.

Commercial supply may occur through:

Regional generic injectable manufacturers
Chinese and Indian API producers
Veterinary pharmaceutical companies
Specialty distributors
Laboratory-reagent suppliers
Government procurement contractors

Supplier identity often differs between the API, finished dosage form, and distribution channel. A company selling kanamycin sulfate laboratory reagent may have no involvement in human pharmaceutical manufacturing.

Because product-level revenue is rarely disclosed, manufacturer comparisons should use operational indicators rather than headline corporate sales:

Indicator	Why it matters
Sterile injectable capability	Determines access to higher-value human products
Regulatory inspection history	Affects procurement eligibility
API integration	Supports lower cost and supply continuity
Government tender participation	Indicates public-sector demand
Veterinary distribution	Measures non-human-market resilience
Geographic registrations	Shows addressable market breadth
Product availability	Distinguishes nominal approval from active sales

What is the financial trajectory for kanamycin sulfate?

The financial trajectory is mature and defensive rather than growth-oriented.

Revenue drivers

Revenue is supported by:

Low-cost procurement in emerging markets
Veterinary use
Existing treatment protocols
Research-reagent consumption
Periodic shortages of alternative antibiotics
Government or institutional tenders

Revenue pressures

Demand is reduced by:

Antimicrobial resistance
Substitution by safer antibiotics
Withdrawal from drug-resistant tuberculosis regimens
Generic price competition
Injectable administration requirements
Toxicity monitoring
Declining use in high-income markets
Regulatory scrutiny of older antibiotics

The likely value chain is low margin. API producers compete primarily on price, production reliability, assay quality, impurity control, and regulatory documentation. Finished-dose manufacturers may obtain better margins in markets with limited competition or procurement barriers, but the overall market remains exposed to tender pricing.

No reliable public data supports a standalone global revenue estimate for kanamycin sulfate. Corporate reports generally combine it with broader antibiotic, hospital, veterinary, or API categories. As a result, the financial trajectory is best assessed through volume, market access, and product availability rather than reported sales.

What generic entry risks exist for kanamycin sulfate?

Generic entry risk is high from a patent perspective and moderate from a manufacturing perspective.

Patent risk

Patent risk is low for conventional kanamycin sulfate products because the original molecule is long off patent. New entrants are unlikely to face a meaningful compound patent challenge.

Regulatory risk

Regulatory risk is higher for injectable products. Key requirements include:

Sterile manufacturing
Validated aseptic processes
Consistent API quality
Impurity characterization
Stability data
Container-closure integrity
Pharmacopoeial compliance
Manufacturing-site inspection readiness

Commercial risk

Commercial risks include:

Small and unstable demand
Low selling prices
Tender concentration
Limited physician use
Alternative antibiotics
Inventory expiration
Dependence on a small number of distributors

A technically capable manufacturer may still find the product unattractive if expected annual volumes do not support regulatory maintenance and sterile production costs.

Which companies are challenging kanamycin sulfate exclusivity?

There is no prominent current Paragraph IV campaign comparable with those involving major branded antibiotics. The competitive pressure comes from ordinary generic substitution, regional manufacturers, veterinary suppliers, and alternative anti-infective products.

The main competitive challenge to kanamycin sulfate is therapeutic substitution rather than patent litigation. In human medicine, newer or less toxic agents have displaced kanamycin in many settings. In tuberculosis, all-oral regimens have reduced demand for injectable aminoglycosides. In veterinary medicine, competition depends on species, country, route of administration, withdrawal periods, and local antimicrobial-use restrictions.

What patent litigation and settlement agreements affect kanamycin sulfate?

No major, widely reported current patent litigation or settlement structure defines the kanamycin sulfate market. A conventional product is unlikely to generate branded-drug litigation because the underlying composition is long off patent and the market is fragmented.

Potential disputes would more likely involve:

Product quality
Manufacturing compliance
Distribution rights
Trademark or labeling issues
Veterinary approvals
Formulation patents
Contract manufacturing
Procurement decisions

Settlement agreements are therefore not a central market-access mechanism for this product.

How does kanamycin sulfate compare with competing aminoglycosides?

Drug	Main commercial position	Relative trend
Kanamycin	Legacy injectable, veterinary, research	Declining in human medicine
Amikacin	More resistant-infection use and broader hospital relevance	Stronger clinical position
Gentamicin	Established hospital and veterinary use	Mature but broader
Tobramycin	Hospital and inhaled ophthalmic applications	More specialized
Streptomycin	Narrow tuberculosis and infectious-disease uses	Declining
Plazomicin	Newer resistant-infection product	Limited but higher-value niche

Kanamycin has a weaker human pharmaceutical position than amikacin because resistance and toxicity have reduced its use. It may retain price advantages in selected settings, but low cost does not offset the loss of guideline support and hospital preference.

What is the geographic coverage of kanamycin sulfate?

Geographic demand is concentrated in countries with:

Active generic injectable markets
Veterinary antibiotic distribution
Local production or import dependence
Lower-cost treatment protocols
Ongoing use of legacy tuberculosis regimens
Research and biotechnology sectors

High-income markets generally have more alternatives and stricter antimicrobial stewardship. Emerging markets may retain demand, but procurement is price-sensitive and regulatory requirements are becoming more demanding.

Geographic diversification can reduce reliance on a single tender or health system. It does not eliminate the underlying risk that demand will continue to shift toward newer agents.

Key Takeaways

Kanamycin sulfate is an old, off-patent aminoglycoside with limited branded-drug value.
No broad, commercially meaningful patent estate protects the underlying molecule.
Paragraph IV litigation and settlement agreements are unlikely to shape the conventional product market.
Human injectable demand is declining, particularly after the move away from injectable tuberculosis regimens.
Veterinary, research, and selected regional generic markets provide the most durable demand.
Manufacturing quality, sterile capacity, regulatory compliance, and supply reliability matter more than patent exclusivity.
Product-level revenue is not publicly reported with sufficient consistency to establish a precise global financial forecast.
The likely financial trajectory is flat to declining for human pharmaceuticals, with greater resilience in veterinary and laboratory segments.

FAQs About Kanamycin Sulfate Market and Patents

Is kanamycin sulfate still commercially available?

Yes. Availability depends on country, dosage form, manufacturer, and regulatory status. It remains present in selected injectable, veterinary, and laboratory markets.

Is kanamycin sulfate a generic drug?

Yes. The active ingredient is long off patent and is generally supplied through generic or non-branded channels.

Can a company still patent kanamycin sulfate?

A company generally cannot obtain a new broad patent on the known molecule. It may seek narrower protection for a novel formulation, manufacturing process, delivery system, or combination.

Is kanamycin sulfate used in tuberculosis treatment?

Its use has declined substantially. International treatment guidance has shifted toward all-oral regimens and away from injectable kanamycin because of toxicity, resistance, and treatment burden.

Does kanamycin sulfate have biosimilar competition?

No. Kanamycin sulfate is a chemically defined small-molecule antibiotic, not a biologic. Competition occurs through generic drug and API suppliers rather than biosimilar manufacturers.

References

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
World Health Organization. (2019). WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization. https://www.who.int/publications/i/item/9789241550529
World Health Organization. (2023). WHO consolidated guidelines on tuberculosis: Module 4, treatment: Drug-resistant tuberculosis treatment. World Health Organization. https://www.who.int/publications/i/item/9789240071311
U.S. National Library of Medicine. (n.d.). Kanamycin. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Kanamycin

US Patents:	0
Tradenames:	4
Applicants:	11
NDAs:	20
Raw Ingredient (Bulk) Api Vendors:	143
Patent Applications:	4,423
DailyMed Link:	kanamycin sulfate at DailyMed

Kanamycin sulfate - Generic Drug Details

What are the generic drug sources for kanamycin sulfate and what is the scope of freedom to operate?

Summary for kanamycin sulfate

Medical Subject Heading (MeSH) Categories for kanamycin sulfate

Anatomical Therapeutic Chemical (ATC) Classes for kanamycin sulfate

US Patents and Regulatory Information for kanamycin sulfate

Kanamycin Sulfate Market Dynamics, Patent Status, and Financial Trajectory